Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
NCT03216096
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Dry Eye Disease
Interventions
DRUG:
Placebo ophthalmic solution and 3% DE-089 ophthalmic solution
Sponsor
Santen Pharmaceutical Co., Ltd.